Acquisition supports Roche’s Pharma Strategy and allows for a range of potentially first and best-in-class therapies across oncology, immunology, and neurology, uniquely positioning Roche in the new field of donor-derived off-the-shelf cell therapiesRoche to acquire Poseida Therapeutics for US $9.00 per share in cash at closing, representing a total equity value of approximately US $1.0 billion Stockholders would also receive a non-tradeable contingent value right (CVR) for up to an aggregate of US $4.00 per share in cash, representing a total deal value of up to approximately US $1.5 billionThe transaction is expected to close in the first quarter of 2025 Basel, 26 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc.

收购支持了罗氏的制药战略，并允许在肿瘤学、免疫学和神经学领域提供一系列潜在的一流和一流的疗法，使罗氏在捐赠者衍生的现成细胞疗法的新领域处于独特地位。罗氏以每股9.00美元的现金收购波塞达治疗公司（Poseida Therapeutics），总股本价值约为10亿美元。股东还将获得不可交易的或有价值权（CVR），每股现金总额高达4.00美元，总交易价值约为15亿美元。交易预计将于2025年11月26日巴塞尔协议第一季度完成罗氏（SIX:RO，ROG；OTCQX:RHHBY）今天宣布，它已经签署了一份最终的合并协议，收购波塞达治疗公司（PoseidaTherapeutics，Inc.）。

(“Poseida”, NASDAQ: PSTX), a public clinical-stage biopharmaceutical company pioneering donor-derived CAR-T cell therapies. Based in San Diego, California, Poseida’s R&D portfolio includes pre-clinical and clinical-stage off-the-shelf (also referred to as allogeneic) CAR-T therapies across several therapeutic areas including haematological malignancies, solid tumours, and autoimmune disease, as well as manufacturing capabilities and technology platforms.

（“波塞达”，纳斯达克：PSTX），一家开创供体来源的CAR-T细胞疗法的公共临床阶段生物制药公司。波塞达位于加利福尼亚州圣地亚哥，其研发组合包括临床前和临床阶段的现成（也称为同种异体）CAR-T疗法，涵盖多个治疗领域，包括血液系统恶性肿瘤，实体瘤和自身免疫性疾病，以及制造能力和技术平台。

The acquisition builds on the existing partnership between Roche and Poseida following the collaboration and licence agreement established in 2022, which focuses on developing off-the-shelf CAR-T cell therapies to address medical needs of patients with haematological malignancies. The joint vision of Poseida, Roche and Genentech, a member of the Roche Group, is to deliver the next generation of off-the-shelf CAR-T cell therapies with increased potency and favourable safety at a scale that can potent.

该收购建立在罗氏和波塞达之间现有的合作伙伴关系基础上，该合作伙伴关系于2022年建立，专注于开发现成的CAR-T细胞疗法，以满足血液系统恶性肿瘤患者的医疗需求。波塞达（Poseida）、罗氏（Roche）和罗氏集团（Roche Group）成员基因泰克（Genentech）的共同愿景是以有效的规模提供下一代现成的CAR-T细胞疗法，提高效力和有利的安全性。

Attachment

附件

26112024_Poseida Aquisition_en

2611224年拥有收购权

Get the latest news and updates to your inbox.

在收件箱中获取最新消息和更新。